CCL21 Antibody

中文名稱：

CCL21兔多克隆抗體
貨號：

CSB-PA004785DA01HU
規格：

￥440
圖片：
IHC image of CSB-PA004785DA01HU diluted at 1:300 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) CCL21 Polyclonal antibody
Uniprot No.：

O00585
基因名：

CCL21
別名：

6Ckine antibody; Beta chemokine exodus 2 antibody; Beta-chemokine exodus-2 antibody; C C motif chemokine ligand 21 antibody; C-C motif chemokine 21 antibody; CCL21 antibody; CCL21_HUMAN antibody; Chemokine (C-C motif) ligand 21 antibody; Chemokine CC motif ligand 21 antibody; CKb9 antibody; ECL antibody; Efficient Chemoattractant for Lymphocytes antibody; SCYA21 antibody; Secondary lymphoid tissue chemokine antibody; Secondary lymphoid-tissue chemokine antibody; SLC antibody; Small inducible cytokine A21 antibody; Small inducible cytokine subfamily A (Cys-Cys); member 21 antibody; Small-inducible cytokine A21 antibody; TCA4 antibody; UNQ784/PRO1600 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human C-C motif chemokine 21 protein (24-134AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，CCL21 Antibody (CSB-PA004785DA01HU)，的標記方式是Non-conjugated。對于CCL21 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA004785DB01HU	CCL21 Antibody, HRP conjugated	ELISA
FITC	CSB-PA004785DC01HU	CCL21 Antibody, FITC conjugated
Biotin	CSB-PA004785DD01HU	CCL21 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:200-1:500

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.
基因功能參考文獻：
1. High CCL21 expression is associated with urinary bladder cancer metastasis. PMID: 28534984
2. Significant associations between the CCL21 rs2812378 G;A polymorphism and rheumatoid arthritis risk were observed in the total population, as well as in subgroup Caucasian population. PMID: 28799100
3. Low CCL21 expression was a potential independent adverse prognostic biomarker for overall survival and progression-free survival for metastatic renal cell carcinoma patients treated with targeted therapy. PMID: 27783999
4. these results demonstrated that CCL21/CCR7 may activate EMT in lung cancer cells via the ERK1/2 signaling pathway. PMID: 28487957
5. CCL21/CCR7 interaction was shown to allow NK cell adhesion to endothelial cells (ECs) and its reduction by hypoxia. PMID: 28416768
6. These data show that CCR7-CCL19/CCL21 axis facilitates retention CD4(+) T lymphocytes at the site of collateral artery remodeling, which is essential for effective arteriogenesis. PMID: 28275068
7. CCL21 correlated significantly with Bladder Pain Syndrome: gene expression in bladder biopsies of patients with Bladder Pain Syndrome was increased in the patients and correlated with clinical profiles. PMID: 26965559
8. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells. PMID: 27157859
9. plasmin cleaves surface-bound CCL21 to release the C-terminal peptide responsible for CCL21 binding to glycosaminoglycans on the extracellular matrix and cell surfaces, thereby generating the soluble form. PMID: 27301418
10. the white pulp regions of ME7-infected spleens were smaller, and contained markedly diminished T zones, as compared to control spleens. Although lymphoid tissue inducer cells were not affected, the expression of both CCL19 and CCL21 was decreased. PMID: 27021907
11. Taken together, these results suggest that SERCA2 contributes to the migration of CCL21-activated Dendritic Cells as an important feature of the adaptive immune response and provide novel insights regarding the role of SERCA2 in Dendritic Cells functions. PMID: 27538371
12. An expanded lymphatic network is capable of enhanced chemoattractant CCL21 production, and lymphangiogenesis will facilitate initial lymph formation favoring increased clearance of fluid in situations of augmented fluid filtration. PMID: 28935759
13. Results provide evidence for an association between an increase level of CCL21 and IP-10 in the blood and pulmonary involvement in systemic lupus erythematosus patients. PMID: 27614982
14. Gata1-KO(DC) DCs have reduced polysialic acid levels on their surface, which is a known determinant for the proper migration of DCs toward CCL21. PMID: 27815426
15. CCL21 and CXCL13 levels are increased in the minor salivary glands of patients with Sjogren's syndrome. PMID: 27782867
16. CCL21/CCR7 interaction contributes to the time-dependent proliferation of PTC cells by upregulating cyclin A, cyclin B1 and cyclin-dependent kinase 1 (CDK1) expression via the extracellular signal-regulated kinase (ERK) pathway associated with iodine. PMID: 27574129
17. CCL21 can facilitate chemoresistance and stem cell property of colorectal cancer cells via the upregulation of P-gp, Bmi-1, Nanog, and OCT-4 through AKT/GSK-3beta/Snail signals. PMID: 27057280
18. CCL21/CCR7 induce VEGF-D up-regulation and promote lymphangiogenesis via ERK/Akt pathway in lung cancer. PMID: 26884842
19. Our findings suggested that MUC1 plays an important role in CCL21-CCR7-induced lymphatic metastasis and may serve as a therapeutic target in esophageal squamous cell carcinoma . PMID: 26667143
20. TGF-beta1 promoted CCL21 expression in lymphatic endothelial cells. CCL21 acted in a paracrine fashion to mediate chemotactic migration of EMT cells toward lymphatic endothelial cells. PMID: 25961925
21. increased expression in mononuclear inflammatory cells isolated from the brain during active stage of experimental autoimmune encephalomyelitis PMID: 25957582
22. The chemotactic interaction between CCR7 and its ligand, CCL21, may be a critical event during progression in pancreatic cancer PMID: 21594558
23. CCL21 gene SNP (rs951005) might confer genetic predisposition to polymyositis patients or such patients with interstitial lung disease in a Chinese Han population. PMID: 26320593
24. over-expression of CCL21 could increased the expressions of antigen presentation-related genes in CK8/18 TECs in MG patients PMID: 26146068
25. Priming by CCL21 restricts lateral mobility of the adhesion receptor LFA-1 and restores adhesion to ICAM-1 nanoaggregates on human mature dendritic cells. PMID: 24945611
26. CCL21/CCR7 pathway activates signallings to up-regulate Slug pathway, leading to the occurrence of epithelial-mesenchymal transition process in human chondrosarcoma PMID: 25556164
27. These results reveal that CCR7 and VEGF-C display a significant crosstalk and suggest a novel role of the CCL21/CCR7 chemokine axis in the promotion of breast cancer-induced lymphangiogenesis. PMID: 25744065
28. CCL21 promotes the metastasis of pancreatic cancer via epithelial-mesenchymal transition. PMID: 25575049
29. Modulation of the chemokines CCL19 and CCL21 represents a potent immunoregulatory treatment approach, and thus represents a novel therapeutic target to stabilize atherosclerotic lesions. PMID: 25473269
30. CCL21/CCR7 interactions might be involved in the response to pressure overload secondary to aortic stenosis. PMID: 25398010
31. CCL21 and CCL19 were significantly increased in serum from ankylosing spondylitis patients. PMID: 25260647
32. overexpressed in myasthenia gravis thymus PMID: 24393484
33. Studied expression of CCR7 and EMT markers in the primary breast carcinoma tissues from patients who underwent radical mastectomy. and investigated whether CCL21/CCR7 induces EMT process during mediating cancer cell invasion or migration in vitro. PMID: 25142946
34. CCL21 was shown to be involved in the induction of ulcerative colitis. Suppression of CCL21 expression decreased damage induced from ulcerative colitis, indicating that CCL21 targeted therapy might be an effective treatment for this disease PMID: 24841666
35. CCL21 rs2812377 was associated with coronary artery disease in a Chinese Han population. PMID: 24990231
36. CCL21 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
37. Although CCL21 levels are elevated, no CCL21-positive cells are observed in patients with eosinophilic pneumonia. PMID: 24111618
38. CCL21 expression was increased in hyperplastic myasthenia gravis thymuses. PMID: 24556356
39. these data suggested an important role of the lymphoid-endothelium-associated chemokine, CCL21, on dendritic cells in the induction of cytotoxic T lymphocytes responses. PMID: 24383579
40. Elevated serum CCL21 correlates with opsoclonus-myoclonus syndrome severity and duration in pediatric opsoclonus-myoclonus syndrome. PMID: 23764550
41. CCL21 expression was found to be an independent prognostic biomarker for CRC. PMID: 23760102
42. In amnion epithelial cells exposed to zinc ferrite nanoparticles there is an increase in CCL21 activation; in situ nanoparticles induce oxidative stress, alterations in cellular membrane and DNA strand breaks. PMID: 24035972
43. Results suggest that the CCL21/CCR7 signaling pathway is involved in renal fibrosis in kidney transplant patients. PMID: 23498789
44. CCL21 attenuates HSV-induced inflammation through up-regulation of CD8+ memory cells. PMID: 22884357
45. CCL21 is a mediator of rheumatoid arthritis angiogenesis. PMID: 22392503
46. oxLDL induces an in vitro downregulation of CCR7 and CCL21, which may play a role in the reduction of dendritic cell migration from the plaques PMID: 22619482
47. High serum levels of CCL21 are independently associated with mortality in chronic and acute post-myocardial infarction heart failure. PMID: 22427939
48. CCL21/CCR7 prevents apoptosis by upregulating the expression of bcl-2 and by downregulating the expression of bax and caspase-3 potentially via the ERK pathway in non-small cell lung cancer cell lines PMID: 22438908
49. CCL21 was more localized to chondrocytes and meniscal cells during the development of osteoarthritis in mice. PMID: 21972019
50. CCL21 structure solved by nuclear magnetic resonance (NMR) contains a conserved chemokine domain followed by an extended, unstructured C-terminus that is not typical of most other chemokines. PMID: 22221265
顯示更多

收起更多
亞細胞定位：

Secreted.
蛋白家族：

Intercrine beta (chemokine CC) family
組織特異性：

Highly expressed in high endothelial venules of lymph nodes, spleen and appendix. Intermediate levels found in small intestine, thyroid gland and trachea. Low level expression in thymus, bone marrow, liver, and pancreas. Also found in tonsil, fetal heart
數據庫鏈接：

HGNC: 10620

OMIM: 602737

KEGG: hsa:6366

STRING: 9606.ENSP00000259607

UniGene: Hs.57907

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human